Mizuho Reiterates “Buy” Rating for Zogenix (NASDAQ:ZGNX)

Zogenix (NASDAQ:ZGNX)‘s stock had its “buy” rating restated by equities researchers at Mizuho in a research report issued on Tuesday, AnalystRatings.com reports. They presently have a $65.00 target price on the stock. Mizuho’s price objective indicates a potential upside of 38.80% from the company’s previous close.

Several other research analysts have also recently weighed in on ZGNX. Piper Jaffray Companies restated a “buy” rating and issued a $64.00 price target on shares of Zogenix in a research note on Friday. JMP Securities set a $69.00 price target on Zogenix and gave the company a “buy” rating in a report on Thursday, September 26th. BidaskClub raised Zogenix from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, November 27th. ValuEngine downgraded Zogenix from a “strong-buy” rating to a “buy” rating in a report on Thursday, November 28th. Finally, Northland Securities reissued a “buy” rating on shares of Zogenix in a research report on Monday, November 25th. One analyst has rated the stock with a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $59.70.

Shares of ZGNX opened at $46.83 on Tuesday. Zogenix has a twelve month low of $33.43 and a twelve month high of $56.50. The company has a market capitalization of $2.07 billion, a P/E ratio of -14.50 and a beta of 1.97. The firm has a 50 day moving average of $45.54 and a 200 day moving average of $44.28. The company has a quick ratio of 3.00, a current ratio of 3.00 and a debt-to-equity ratio of 0.04.

Zogenix (NASDAQ:ZGNX) last released its quarterly earnings data on Thursday, November 7th. The company reported ($6.75) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.05) by ($5.70). The company had revenue of $0.63 million during the quarter, compared to analyst estimates of $0.39 million. During the same quarter in the previous year, the business earned ($1.08) earnings per share. On average, sell-side analysts expect that Zogenix will post -3.73 EPS for the current year.

In other Zogenix news, Director James B. Breitmeyer sold 5,000 shares of the business’s stock in a transaction dated Monday, November 25th. The stock was sold at an average price of $50.00, for a total transaction of $250,000.00. Following the completion of the sale, the director now directly owns 6,250 shares in the company, valued at approximately $312,500. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Stephen J. Farr sold 34,225 shares of the business’s stock in a transaction dated Monday, November 25th. The shares were sold at an average price of $50.00, for a total value of $1,711,250.00. Following the sale, the chief executive officer now owns 90,752 shares of the company’s stock, valued at $4,537,600. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 54,225 shares of company stock valued at $2,681,250. Company insiders own 4.40% of the company’s stock.

Large investors have recently modified their holdings of the company. Advisor Group Inc. boosted its holdings in shares of Zogenix by 383.1% in the second quarter. Advisor Group Inc. now owns 942 shares of the company’s stock worth $45,000 after buying an additional 747 shares during the last quarter. Point72 Hong Kong Ltd bought a new position in Zogenix in the second quarter worth approximately $61,000. Tower Research Capital LLC TRC bought a new position in Zogenix in the second quarter worth approximately $76,000. Russell Investments Group Ltd. purchased a new position in shares of Zogenix during the 3rd quarter worth $80,000. Finally, Panagora Asset Management Inc. purchased a new position in shares of Zogenix during the 2nd quarter worth $116,000.

About Zogenix

Zogenix, Inc, a pharmaceutical company, develops and commercializes therapies for the treatment of transformative central nervous system disorders in the United States. Its lead product candidate is the Fintepla/ZX008, a low-dose fenfluramine, which is in Phase III clinical trials for the treatment of seizures associated with Dravet syndrome.

Further Reading: Momentum Indicators

Analyst Recommendations for Zogenix (NASDAQ:ZGNX)

Receive News & Ratings for Zogenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zogenix and related companies with MarketBeat.com's FREE daily email newsletter.